121-135 of 282
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®Personalizing Care for Large Cell Neuroendocrine Carcinoma
Junaid Arshad, MD, MS
Pediatric Sickle Cell Disease: Analyzing Trends in Medication Utilization
Project Oncology®Pediatric Sickle Cell Disease: Analyzing Trends in Medication Utilization
Abiodun Ologunowa
Exploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
NeuroFrontiersExploring Circulating CD34+ Cells as a Biomarker of Fracture Risk in DMD
Quantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
NeuroFrontiersQuantifying the Hidden Cost Burden of Duchenne Muscular Dystrophy on U.S. Households
Cardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
NeuroFrontiersCardiopulmonary Exercise Testing Sheds Light on Early Physiologic Decline in Duchenne Muscular Dystrophy
Sickle Cell Disease Care: Balancing Disease-Modifying and Curative Therapies
Project Oncology®Sickle Cell Disease Care: Balancing Disease-Modifying and Curative Therapies
Yogindra Persuad
- advertisement
Improving Health Literacy to Empower Adolescents With Sickle Cell Disease
Project Oncology®Improving Health Literacy to Empower Adolescents With Sickle Cell Disease
Nidhi Bhatt
Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Project Oncology®Cardiac Complications in Sickle Cell Disease: Emerging Evidence and Risks
Parul Rai
Balancing Benefits and Risks in Emerging Sickle Cell Therapies
Project Oncology®Balancing Benefits and Risks in Emerging Sickle Cell Therapies
Yogindra Persuad
The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Project Oncology®The Transition from Pediatric to Adult Care for Patients with Sickle Cell Disease
Nidhi Bhatt
Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
Project Oncology®Sickle Cell Disease Care: Examining Hydroxyurea and Chronic Transfusions
Parul Rai
Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
Project Oncology®Building a Multidisciplinary Care Team for Sickle Cell Disease Patients
Nidhi Bhatt
- advertisement
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Identifying CIDP: A Guide to Risk Profiles and Clinical Presentation
On the Frontlines of CIDPIdentifying CIDP: A Guide to Risk Profiles and Clinical Presentation
Nicolas Dubuisson, MD
Ryan Quigley
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Clinician's RoundtableConsensus and Standards to Improve Continuity of Care in Sickle Cell Disease
